1. Introduction {#sec1}
===============

Systemic lupus erythematosus (SLE) is a chronic and inflammatory autoimmune disease characterized by antinuclear autoantibody production and a multitude of immune-complex deposition, which is involved in multisystem; such as the skin, kidney, and brain; and caused organs/tissue destruction \[[@B1], [@B2]\]. Until now, the etiology of SLE is still not fully understood. A large body of literatures have suggested that the interactions between exogenous (infectious triggers, ultraviolet radiation, and dietary habit) and endogenous sources (hereditary susceptibility, endocrine disorders and disturbed status of oxidative metabolism, and autoimmune responsiveness sympathetic nervous system) are responsible for the pathogenesis and development of SLE \[[@B3]--[@B9]\].

Melatonin (MTN), as one of the major neuroendocrine hormones, is mainly produced and secreted by the pineal gland; it allows to regulate the circadian day-night rhythm and seasonal biorhythms and is also a key player in the neuroendocrine-immune pathway \[[@B10], [@B11]\]. Several studies have suggested the important role of MTN on the regulation of the immune system; it can skew the immune response by repressing the production of several proinflammatory cytokines (such as tumor necrosis factor- (TNF-) *α*, interleukin- (IL-) 1*β*, and IL-6), as well as blocking the DNA-binding activity of NF-*κ*B both *in vitro* and *in vivo*, exerting an anti-inflammatory effect \[[@B11]--[@B16]\].

Previous studies have investigated the underlying role of MTN in SLE. Lechner et al. observed an increased MTN level in MRL/MP-fas lupus-prone mice (represents an animal model for human autoimmune diseases, which spontaneously develops lupus-like glomerulonephritis, systemic vasculitis, arthritis, and sialadenitis) during the light phase; under the regulation of MTN, the levels of autoantibodies were reduced, and the histological changes were improved in female lupus MRL/MP-fas lupus-prone mice \[[@B17]\]. MTN is able to inhibit IgM, anti-dsDNA, and anti-histone antibodies, thus, decreases the levels of IL-6 and IL-13 and increases the IL-12 levels \[[@B18]\]. In patients with SLE, a lower daily MTN level was observed as compared to healthy controls, and this decreased daily MTN level inversely correlated with the systemic lupus erythematosus disease activity index (SLEDAI) \[[@B19]\]. In addition, study has also revealed the seasonal pattern of MTN levels in SLE, with an elevated daily plasma MTN levels in December than in June \[[@B20]\]. These findings provided the possible evidence that MTN might play a potential role in the pathogenesis of SLE.

The synthesis and function of MTN mainly depend on three MTN pathway genes, *MTN receptors 1a/1b* (*MTNR1a/MTNR1b*) are largely responsible for mediating the downstream effects of MTN, and arylalkylamine N-acetyltransferase (*AANAT*) is the major enzyme in MTN synthesis \[[@B21], [@B22]\]. The genetic association of MTN genes with some diseases has been demonstrated in several studies, including SLE, multiple sclerosis (MS), breast cancer, and major depression \[[@B23]--[@B26]\]. Nevertheless, associations between genetic variation in MTN pathway genes and SLE susceptibility have not been determined.

In the present study, we conducted a case--control study to comprehensively evaluate the role of common genetic variation in the *MTNR1a*, *MTNR1b*, and *AANAT* genes to SLE susceptibility in a Chinese population.

2. Materials and Methods {#sec2}
========================

2.1. Study Subjects and Methods {#sec2.1}
-------------------------------

This case--control genotyping study recruited a total of 988 subjects (495 SLE patients and 493 healthy controls). The sample size and power calculation of the study were computed by power and sample size program, where both the minor allele frequency (MAF) and statistical significant level were set as 0.05, odds ratio (OR) was 1.5, case and control ratio was 1 : 1 and when the statistical power was 0.8, the computed sample size for cases was 451. In addition, we also evaluated the statistical power for the 496 included cases, and the results showed that the computed statistical power was 0.833.

Patients with SLE were recruited from the Department of Rheumatology and Immunology at Anhui Provincial Hospital, The First Affiliated Hospital of Anhui Medical University. The diagnosis of SLE was established by the presence of four or more 1997 revised American College of Rheumatology (ACR) classification criteria \[[@B27]\]. Patients with viral infections and any history of cancer, pregnancy, and recurrent spontaneous abortions were excluded based on reviews of their appropriate history. The normal controls consisted of age, gender, and ethnicity-matched healthy individuals who belonged to the same geographical area as that of cases; normal controls were excluded if they had a family history of SLE or any other autoimmune disease and history of any chronic or lifestyle diseases like depression, hypothyroidism, hypertension, diabetes mellitus, and tuberculosis (TB). Demographics, clinical features, and related laboratory results were obtained from hospital medical records and then reviewed by experienced physicians.

The Ethical Committee of Anhui Medical University (Hefei, Anhui, China) approved this study. All the study subjects provided informed consent to participate in this study.

All studies on humans described in the present manuscript were carried out with the approval of the responsible ethics committee and in accordance with the national law and the Declaration of Helsinki 1975 (in its current, revised form).

2.2. MTN Pathway Gene\'s SNP Selection and Genotyping {#sec2.2}
-----------------------------------------------------

Ensembl Gene Browser 37 (GRCh37) (<http://grch37.ensembl.org/index.html>) (Ensembl Archive Release 90) was implemented to acquire the genetic and location information of *MTNR1a*, *MTNR1b*, and *AANAT* genes \[[@B28]\], and linkage pedigree file (PED) and marker information file were downloaded. Then, the downloaded files were used to select the tag SNPs in Haploview 4.2 software (Broad Institute, Cambridge, MA, USA), with a MAF above 0.05 in Chinese Han population (CHB) of Beijing, linkage disequilibrium (LD) with an *r*^2^ threshold of 0.8. A total of 46 tag SNPs (23 *MTNR1a* tag SNPs, 13 *MTNR1b* tag SNPs, and 10 *AANAT* tag SNPs) were captured for further evaluation. The function prediction for 46 tag SNPs was assessed by the online bioinformatics tools (<https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html>) \[[@B29]\]; the basic information of these tag SNPs is shown in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}. In addition, the published literatures about the MTN pathway gene\'s polymorphisms were also carefully reviewed. Based on one or more of the following criteria: assumed functionality (located in the regulatory regions, for example, 3′-untranslated regions (UTR), 5′-UTR, or amino acid change), *r*^2^ ≥ 0.80 and MAF ≥ 5%, as well as previous studies reported SNPs), the five tag SNPs (rs10030173, rs2119882, rs2165667, rs4861722, and rs6847693) in *MTNR1a* gene, three tag SNPs (rs1562444, rs10830962, and rs3781637) in *MTNR1b* gene, and three tag SNPs (rs8150, rs3760138, and rs12942767) in *AANAT* gene were finally chosen for further genotyping.

Genomic DNA was extracted from peripheral venous blood of patients and healthy controls using a QIAGEN kit (QIAGEN, Hilden, Germany) based on the manufacturer\'s instructions, and quantification and concentration of DNA was determined using NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, USA). Qualified sample requirements were shown as follows: concentration greater than 50 ng/*μ*l, total amount greater than 600 ng, and no obvious degradation.

Genotyping was performed in using improved multiple ligase detection reaction (iMLDR), with technical support from the Center for Genetic & Genomic Analysis, Genesky Biotechnologies Inc., Shanghai. A multiplex PCR-ligase detection reaction method was used in the iMLDR. For each SNP, the alleles were distinguished by different fluorescent labels of allele-specific oligonucleotide probe pairs. Different SNPs were further distinguished by different extended lengths at the 3′ end. Two negative controls were set: one with double-distilled water as template and the other with DNA sample without primers while keeping all other conditions the same in one plate. Duplicate tests were designed, and the results were consistent. A random sample accounting for \~3% of the total DNA samples was directly sequenced using BigDye Terminator version 3.1 and an ABI3730XL automated sequencer (Applied Biosystems) to confirm the results of iMLDR.

2.3. Plasma MTN Determination {#sec2.3}
-----------------------------

Blood samples were collected from 5 ml of whole blood of all study subjects and then stored at -80°C until assayed. Plasma MTN concentration was determined by enzyme-linked immunosorbent assay (ELISA) kits (the lower detection limit was 0.1 pg/ml) which were purchased from Anhui Xinle Biotechnology Co. Ltd.; the results of MTN were expressed as picograms per milliliter. The interassay and intraassay variation coefficients of the ELISA kit of our study were 6.9% and 7.6%, respectively.

2.4. Statistical Analysis {#sec2.4}
-------------------------

The allelic and genotypic association analyses between SLE patients and healthy controls were performed in using the Chi-square or Fisher\'s exact test. Logistic regression analyses were utilized to calculate odds ratios (ORs), and 95% confidence intervals (CIs) for the association between genotype and SLE susceptibility, additive, dominant, recessive, and allelic models were also considered. A nonparametric test was used to compare the difference in plasma MTN levels among patients with different genotypes. Statistical analysis was implemented with the use of the SPSS (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp.).

Hardy--Weinberg equilibrium (HWE) among controls was assessed by comparing the observed-to-expected genotype frequencies using the Chi-square test. Online software SHEsis was used for haplotype analyses of each MTN pathway genes; all the haplotypes with a frequency \< 0.03 were ignored in the analysis \[[@B30]\]. All results with a two-tailed *P* \< 0.05 were considered to be statistically significant. The Bonferroni correction was used for multiple testing.

3. Results {#sec3}
==========

3.1. Characteristics of the Study Population {#sec3.1}
--------------------------------------------

The present study recruited 988 subjects, with 495 SLE patients and 493 healthy controls. In SLE patients, there were 57 males and 438 females with a median age of 37.00 (28.00, 46.00) years and the median disease duration was 4.10 (range from 1.05 to 9.06) years, while there were 55 males and 434 females with the median age of 38.00 (30.00, 47.00) in healthy controls. No significant differences in gender and age distribution were observed between SLE patients and normal controls **(**[Table 1](#tab1){ref-type="table"}**)**. The major clinical manifestations of SLE were immunological abnormality (73.1%), hematological abnormality (68.3%), arthritis (49.5%), malar rash (45.3%), photosensitivity (39.0%), and renal abnormality (37.2%). In control groups, the presence of observed genotype frequencies of all included tag SNPs was distributed in compliance with the HWE (all *P* \> 0.05).

3.2. Association of MTNR1a/b and AANAT Gene\'s Polymorphisms with Susceptibility to SLE {#sec3.2}
---------------------------------------------------------------------------------------

There were no significant differences in allele and genotype distribution of 8 tag SNPs in *MTNR1a/b* genes between SLE and healthy controls (all *P* \> 0.05) ([Table 2](#tab2){ref-type="table"}). However, when analyzing the allele and genotype frequency of 3 tag SNPs in *AANAT* genes, the results showed that two SNPs of rs8150 and rs3760138 were associated with the risk of SLE susceptibility, where CC carriers of rs8150 had a lower risk as compared to GG (OR = 0.537, 95% CI: 0.361, 0.799) (*P* = 0.002), whereas GG carrier of rs3760138 had an increased risk as compared to TT (OR = 1.823, 95% CI: 1.154, 2.880) (*P* = 0.010), but we did not observe other positive findings regarding the SNPs of rs12942767 ([Table 3](#tab3){ref-type="table"}).

3.3. Association of MTNR1a/b and AANAT Gene\'s Polymorphisms with Clinical Features in Patients with SLE {#sec3.3}
--------------------------------------------------------------------------------------------------------

Case-only analysis was conducted to further explore the genetic association of *MTNR1a/b* and *AANAT* gene\'s polymorphisms with specific clinical features of SLE. In *MTNR1a/b* genes, a significantly increased AA genotype frequency of rs2165667 (*MTNR1a*) and A allele frequency of rs1562444 (*MTNR1b*) were found in patients with arthritis than those without (both *P* = 0.024). In addition, the frequency of CC/CG genotype in rs10830962 (*MTNR1b*) was significantly lower in patients with malar rash than in those without (*P* = 0.018). In terms of the genetic association of *AANAT* gene with clinical features of SLE, there was a higher GG/GT/TT genotype distribution of rs3760138 in patients with positive immunological abnormality than those with negative (*P* = 0.024); the C/G allele and CC/CG/GG genotype frequency of rs8150 appeared to have a significantly increased risk in patients with positive hematological abnormality compared with those with negative (*P* = 0.039, *P* = 0.010, respectively). Nevertheless, no other positive findings were revealed regarding the *MTNR1a/b* and *AANAT* gene\'s polymorphisms with SLE clinical features ([Table 4](#tab4){ref-type="table"}).

3.4. Association of Plasma MTN Concentrations with Genotypes in Patients with SLE {#sec3.4}
---------------------------------------------------------------------------------

The results indicated that, in patients with SLE, there was a significant difference of MTN level among genotype of AA, AG, and GG in rs1562444 (*MTNR1b*) (*P* = 0.001), which GG genotype showed an elevated MTN concentration than in AA and AG genotype (20.57 pg/ml *vs* 14.08 pg/ml *vs* 10.36 pg/ml). However, no significant differences of plasma MTN concentrations were observed in other SNPs between patients ([Table 5](#tab5){ref-type="table"}).

3.5. Haplotype Analyses {#sec3.5}
-----------------------

The haplotype of tag SNPs in *MTNR1a/b* and *AANAT* genes was constructed by using SHEsis software. Haplotype analyses implied that haplotype CCTAT (*MTNR1a*), CTAGT (*MTNR1a*), and GGG (*AANAT*) were significantly associated with the increased risk in SLE susceptibility, but TCTAT (*MTNR1a*) and CTG (*AANAT*) appeared to be a protective haplotype (all *P* \< 0.05). However, no positive findings of other haplotypes were observed (Tables [6](#tab6){ref-type="table"}[](#tab7){ref-type="table"}--[8](#tab8){ref-type="table"}).

4. Discussion {#sec4}
=============

The neuroendocrine-immune system is regarded as a fundamental network supporting the health state that could play an important role in the development of autoimmune disorders \[[@B31], [@B32]\]. MTN, as one of the pineal gland-driven hormones, secreted in a circadian rhythm and regulated by photoperiod with the highest peak at midnight and lowest level after sunrise, acting mainly as a regulator for sleeping rhythm \[[@B33]--[@B36]\]. In recent years, the bidirectional associations between the pineal gland and the immune system have been suggested to depend on the immune-modulating effect of MTN and the pineal regulation by different lymphokines \[[@B37]\]. MTN might have a direct effect on immune-competent cells, thus, fulfilling critical roles on the development and progression of autoimmune diseases \[[@B38]--[@B40]\].

Our previous study has evaluated the level of MTN in patients with SLE as compared to healthy controls. Although there was no significant difference in MTN concentration between those two groups, we observed a slightly lower level of MTN in SLE patients than in healthy controls; in addition, an inverse correlation of MTN concentration with IgM was also revealed \[[@B41]\]. Similarly, Robeva et al. revealed that there was a decreased daily MTN level in women with SLE and found an inverse relationship between daily MTN concentrations and disease activity \[[@B19]\]. In the subarctic region, the study has demonstrated the presence of seasonal variations in daily MTN level, where the increased level of MTN was discovered in December than that in June \[[@B20]\]. These evidences suggest that the change of MTN concentration may be involved in the pathogenesis of SLE.

*MTNR1a/b* and *AANAT* play an important role during the pathway of MTN from biosynthesis to its functioning; the former *MTNR1a/b* genes are largely responsible for mediating the downstream effects of MTN, while the latter *AANAT* gene is the major enzyme in MTN synthesis. Several previous studies have investigated the underlying role of MTN pathway genes in a number of human diseases. In SLE, primary study, performed by Tanev et al., has demonstrated no significant differences in allelic and genotype distribution of *MTNR1b* gene (rs1562444, rs10830962, and rs10830963) polymorphisms between 109 patients with SLE and 101 controls, yet, in SLE patients, C/C genotype of rs10830963 in *MTNR1b* gene was related to increased prevalence of leucopenia compared to C/G and G/G genotype; the rs10830963 G/G carriers had a lower number of lupus criteria than in those with C/C genotype \[[@B25]\]. The *MTNR1b* rs10830962 and rs10830963 polymorphisms have been predominantly investigated in the context of metabolic disorders, of which rs10830962 and rs10830963 G alleles were reported to associate with reduced insulin secretion, increased fasting plasma glucose concentrations, and increased risk for diabetes in different populations \[[@B42]--[@B44]\]. In autoimmune diseases of multiple sclerosis (MS), there were no significant allelic associations of SNPs rs4753426 and rs10830963 in *MTNR1b* gene with susceptibility to MS, but the rs10830963-rs4753426 G-T haplotype associated with the risk of MS in the progressive MS group \[[@B23]\]. Deming et al. analyzed the MTN pathway gene\'s polymorphisms in human breast cancer patients, and they supported that AA genotype of *MTNR1b* rs10765576 was associated with a decreased risk of breast cancer, the GG genotype in premenopausal women correlated with an increased risk for breast cancer, and however, in postmenopausal women, the GG genotype were related with a decreased risk of breast cancer; they did not observe any significant breast cancer associations for variants in the *AANAT* gene \[[@B24]\]. In patients with major depression, the two SNPs of *AANAT* (rs3760138 and rs4238989) were reported to be associated with an increased contribution to major depression \[[@B26]\].

In the present study, the tag SNPs of rs8150 and rs3760138 in *AANAT* gene were associated with genetic susceptibility to SLE, but no genetic association regarding the other nine tag SNPs with SLE susceptibility was found. Case-only analysis indicated that AA genotype frequency in rs2165667 (*MTNR1a*) AA genotype and rs1562444 (*MTNR1b*) A/G allele frequency were at increased risk for arthritis and rs10830962 (*MTNR1b*) CC/CG genotype was at decreased risk for malar rash. In *AANAT* gene, rs3760138 GG/GT/TT genotype associated with positive immunological abnormality than those with negative, and rs8150 CC/CG/GG genotype and its C/G allele appeared to have an increased risk for hematological abnormality. Moreover, we also found that there was a significant difference of MTN concentration samong the genotype of AA, AG, and GG in rs1562444 (*MTNR1b*), where the GG genotype showed an elevated MTN concentration than in AA and AG genotype. We might hypothesize that the rs1562444 variant polymorphisms lead to the aberrant expression of MTN in patients with SLE. Later, the haplotype of *MTNR1a/b* and *AANAT* was identified; *MTNR1a* gene haplotype of CCTAT and CTAGT, and *AANAT* gene haplotype of GGG showed an increased risk in SLE susceptibility, but haplotype of TCTAT (*MTNR1a*) and CTG (*AANAT*) appeared to have a protective role.

The present study investigated the genetic association of SNPs in MTN pathway genes (*MTNR1a/b* and *AANAT*) with SLE susceptibility. However, there are some limitations in our study. First, the current study might be due to inherent selection biases such as a relative small sample size, the limited number of variables accounted, and the lack of information regarding body mass index (BMI) in healthy controls. Second, the potential confounding factors, such as type of treatments and concomitant infections, may have an effect on the level of MTN. Furthermore, although our study represented significant genetic variations regarding *AANAT* gene in Chinese SLE patients, the detailed mechanism about potential effect of the *AANAT* gene variation on SLE is scarce.

In conclusion, our study demonstrated that, in the Chinese population, the genetic polymorphism of MTN pathway genes associated with the susceptibility to SLE, as well as with specific clinical manifestations, suggesting that the MTN pathway genes might be involved in the pathogenesis and development of SLE. However, further large sample size studies in other population are needed to further reveal the significance of MTN pathway gene\'s polymorphisms in SLE. In addition, related mechanism researches are necessary to better understand the function of the MTN pathway gene SNP in different immune cell types and to evaluate its correlation with clinical features.
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###### 

Supplementary Table 1: characteristics of the 46 Tag SNPs.

###### 

Click here for additional data file.

###### 

Demographic characteristics and clinical features of patients with SLE and control subjects.

  Parameters                            Patients with SLE (*n* = 495)   Healthy controls (*n* = 493)
  ------------------------------------- ------------------------------- ------------------------------
  Demographic characteristics                                           
   Age (year)                           37.00 (28.00, 46.00)^∗∗^        38.00 (30.00, 47.00) ^∗∗^
   Female, *n* (%)                      438 (88.5)                      434 (88.0)
   Male, *n* (%)                        58 (11.5)                       59 (12.0)
   Disease duration (year)              4.10 (1.05, 9.06) ^∗∗^          NA
   BMI (kg/m^2^)                        21.48 (19.72, 23.43) ^∗∗^       NA
   SLEDAI                               11.40 ± 9.07^∗^                 NA
  Disease manifestations                                                NA
   Malar rash, *n* (%)                  224 (45.3)                      NA
   Discoid rash, *n* (%)                94 (19.0)                       NA
   Photosensitivity, *n* (%)            193 (39.0)                      NA
   Oral ulcers, *n* (%)                 119 (24.0)                      NA
   Arthritis, *n* (%)                   245 (49.5)                      NA
   Serositis, *n* (%)                   45 (9.1)                        NA
   Renal abnormality, *n* (%)           184 (37.2)                      NA
   Neurological abnormality, *n* (%)    21 (4.2)                        NA
   Hematological abnormality, *n* (%)   338 (68.3)                      NA
   Immunological abnormality, *n* (%)   362 (73.1)                      NA

BMI: Body mass index; *n*: number; SLE: systemic lupus erythematosus; SLEDAI: systemic lupus erythematosus disease activity index. ^∗^Data with normal distribution were described as mean and standard deviation (SD). ^∗∗^Data with skewed distribution were described as median and interquartile range (IQR).

###### 

Genotype frequencies of *MTNR1a/b* SNPs in SLE patients and healthy controls.

  SNPs                    Analyzed model         SLE                    Control                OR (95% CI)            *P* value^∗^
  ----------------------- ---------------- ----- ---------------------- ---------------------- ---------------------- --------------
  rs10030173 (*MTNR1a*)   Genotypes        CC    107                    93                     1.308 (0.916, 1.867)   0.139
  CT                      242              234   1.176 (0.883, 1.565)   0.267                                         
  TT                      146              166   1.000                                                                
  Additive model          CC               107   93                     1.308 (0.916, 1.867)   0.139                  
  TT                      146              166   1.000                                                                
                                                                                                                      
  rs2119882 (*MTNR1a*)    Genotypes        CC    71                     78                     0.792 (0.542, 1.156)   0.226
  CT                      217              235   0.803 (0.612, 1.054)   0.114                                         
  TT                      207              180   1.000                                                                
  Additive model          CC               71    78                     0.792 (0.542, 1.156)   0.226                  
  TT                      207              180   1.000                                                                
                                                                                                                      
  rs2165667 (*MTNR1a*)    Genotypes        AA    230                    200                    1.267 (0.849, 1.890)   0.246
  AT                      206              228   0.995 (0.667, 1.484)   0.982                                         
  TT                      59               65    1.000                                                                
  Additive model          AA               230   200                    1.267 (0.849, 1.890)   0.246                  
  TT                      59               65    1.000                                                                
                                                                                                                      
  rs4861722 (*MTNR1a*)    Genotypes        AA    25                     28                     0.978 (0.548, 1.743)   0.939
  GA                      165              189   1.243 (0.707, 2.183)   0.450                                         
  GG                      304              274   1.000                                                                
  Additive model          AA               25    28                     0.978 (0.548, 1.743)   0.939                  
  GG                      304              274   1.000                                                                
                                                                                                                      
  rs6847693 (*MTNR1a*)    Genotypes        CC    182                    167                    0.868 (0.658, 1.145)   0.318
  CT                      229              242   0.918 (0.635, 1.326)   0.647                                         
  TT                      84               84    1.000                                                                
  Additive model          CC               182   167                    0.868 (0.658, 1.145)   0.318                  
  TT                      84               84    1.000                                                                
                                                                                                                      
  rs1562444 (*MTNR1b*)    Genotypes        AA    254                    262                    1.039 (0.659, 1.636)   0.870
  GA                      199              186   1.146 (0.720, 1.826)   0.565                                         
  GG                      42               45    1.000                                                                
  Additive model          AA               254   262                    1.039 (0.659, 1.636)   0.870                  
  GG                      42               45    1.000                                                                
                                                                                                                      
  rs10830962 (*MTNR1b*)   Genotypes        CC    176                    145                    1.349 (0.951, 1.913)   0.093
  CG                      220              236   1.036 (0.746, 1.438)   0.834                                         
  GG                      99               110   1.000                                                                
  Additive model          CC               176   145                    1.349 (0.951, 1.913)   0.093                  
  GG                      99               110   1.000                                                                
                                                                                                                      
  rs3781637 (*MTNR1b*)    Genotypes        CC    11                     11                     1.009 (0.420, 2.424)   0.984
  CT                      111              110   1.003 (0.429, 2.341)   0.995                                         
  TT                      373              372   1.000                                                                
  Additive model          CC               11    11                     1.009 (0.420, 2.424)   0.984                  
  TT                      373              372   1.000                                                                

SLE: systemic lupus erythematosus; SNPs: single-nucleotide polymorphisms; OR: odds ratio; *MTNR1a*: *melatonin receptor 1a*; *MTNR1b*: *melatonin receptor 1b.*^∗^The *P* values are not corrected for multiple testings, Bonferroni corrected *P* = 0.0167.

###### 

Genotype frequencies of *AANAT* SNPs in SLE patients and healthy controls.

  SNPs             Analyzed model         SLE                    Control                OR (95% CI)            *P* value^∗^
  ---------------- ---------------- ----- ---------------------- ---------------------- ---------------------- --------------
  rs8150           Genotypes        CC    176                    202                    0.537 (0.361, 0.799)   **0.002**
  GC               232              236   1.128 (0.860, 1.480)   0.384                                         
  GG               86               53    1.000                                                                
  Additive model   CC               176   202                    0.537 (0.361, 0.799)   **0.002**              
  GG               86               53    1.000                                                                
                                                                                                               
  rs3760138        Genotypes        GG    271                    223                    1.823 (1.154, 2.880)   **0.010**
  GT               188              216   1.306 (0.820, 2.078)   0.261                                         
  TT               36               54    1.000                                                                
  Additive model   GG               271   223                    1.823 (1.154, 2.880)   **0.010**              
  TT               36               54    1.000                                                                
                                                                                                               
  rs12942767       Genotypes        GG    450                    447                    ---                    1.000
  GA               44               46    ---                    1.000                                         
  AA               1                0     1.000                                                                
  Additive model   GG               450   447                    ---                    1.000                  
  AA               1                0     1.000                                                                

SLE: systemic lupus erythematosus; SNPs: single-nucleotide polymorphisms; OR: odds ratio; *AANAT*: *arylalkylamine N-acetyltransferase*. ^∗^The *P* values are not corrected for multiple testings, Bonferroni corrected *P* = 0.0167.

###### 

The positive findings on association of clinical characteristics with genotype and allele frequencies in *MTNR1a/b* and *AANAT* genes.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene (SNPs)             Allele\   Clinical features           Group      Genotypes (*n*)   *P* value   Alleles (*n*)   *P* value               
                          (M/m)                                                                                                                  
  ----------------------- --------- --------------------------- ---------- ----------------- ----------- --------------- ----------- ----- ----- -----------
  rs2165667 (*MTNR1a*)    A/T       Arthritis                   Positive   125               87          33              **0.024**   337   153   0.318

  Negative                105       119                         26                           329         171                                     

                                                                                                                                                 

  rs10830962 (*MTNR1b*)   C/G       Malar rash                  Positive   77                90          57              **0.018**   244   204   0.055

  Negative                99        130                         42                           328         214                                     

                                                                                                                                                 

  rs1562444 (*MTNR1b*)    A/G       Arthritis                   Positive   136               94          15              0.072       366   124   **0.024**

  Negative                118       105                         27                           341         159                                     

                                                                                                                                                 

  rs3760138 (*AANAT*)     G/T       Immunological abnormality   Positive   198               131         33              **0.024**   527   197   0.264

  Negative                73        57                          3                            203         63                                      

                                                                                                                                                 

  rs8150 (*AANAT*)        C/G       Hematological abnormality   Positive   131               155         51              **0.039**   417   257   **0.010**

  Negative                45        77                          35                           167         147                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

SNPs: single-nucleotide polymorphisms; *MTNR1a*: *melatonin receptor 1a*; *MTNR1b*: *melatonin receptor 1b*; *AANAT*: *arylalkylamine N-acetyltransferase.*

###### 

Association of plasma MTN levels with genotype in *MTNR1a/b* and *AANAT.*

  SNPs                    Genotypes   Number                 Plasma MTN levels (pg/ml)   *P* value
  ----------------------- ----------- ---------------------- --------------------------- -----------
  rs10030173 (*MTNR1a*)   CC          19                     14.22 (9.23, 20.57)         0.946
  CT                      45          13.45 (9.91, 19.06)                                
  TT                      19          12.39 (10.27, 18.69)                               
                                                                                         
  rs2119882 (*MTNR1a*)    CC          9                      12.19 (9.54, 25.08)         0.312
  CT                      44          13.79 (10.34, 20.00)                               
  TT                      30          10.82 (9.16, 16.33)                                
                                                                                         
  rs2165667 (*MTNR1a*)    AA          32                     10.69 (8.41, 16.12)         0.079
  AT                      44          13.24 (10.39, 19.91)                               
  TT                      7           19.38 (10.49, 28.21)                               
                                                                                         
  rs4861722 (*MTNR1a*)    AA          6                      15.47 (8.24, 34.58)         0.640
  GA                      30          11.74 (10.19, 16.35)                               
  GG                      47          13.71 (9.91, 21.46)                                
                                                                                         
  rs6847693 (*MTNR1a*)    CC          25                     10.62 (9.08, 16.41)         0.333
  CT                      47          13.45 (10.36, 20.20)                               
  TT                      11          18.37 (8.59, 21.95)                                
  CT                      1           11.07                                              
                                                                                         
  rs1562444 (*MTNR1b*)    AA          41                     14.08 (10.63, 20.08)        **0.001**
  AG                      35          10.36 (8.94, 13.86)                                
  GG                      7           20.57 (18.37, 28.21)                               
                                                                                         
  rs10830962 (*MTNR1b*)   CC          25                     13.71 (10.32, 22.10)        0308
  CG                      49          11.58 (9.80, 18.30)                                
  GG                      9           15.57 (10.05, 33.40)                               
                                                                                         
  rs3781637 (*MTNR1b*)    CC          3                      18.37 (13.71, 28.21)        0.392
  CT                      16          13.12 (8.57, 20.27)                                
  TT                      64          12.55 (10.25, 17.83)                               
                                                                                         
  rs8150 (*AANAT*)        CC          36                     13.68 (10.28, 23.20)        0.518
  GC                      34          11.88 (9.62, 18.45)                                
  GG                      13          13.04 (10.44, 14.82)                               
                                                                                         
  rs3760138 (*AANAT*)     GG          45                     12.19 (9.78, 17.09)         0.802
  GT                      31          13.45 (10.05, 21.95)                               
  TT                      7           14.27 (12.01, 21.46)                               
                                                                                         
  rs12942767 (*AANAT*)    GA          5                      13.03 (9.88, 16.83)         0.878
  GG                      78          13.07 (9.92, 19.59)                                

SNPs: single-nucleotide polymorphisms; *M*: median; MTN: melatonin; *MTNR1a*: *melatonin receptor 1a*; *MTNR1b*: *melatonin receptor 1b*; *AANAT*: *arylalkylamine N-acetyltransferase.*

###### 

Haplotype analysis of five SNPs in *MTNR1a* gene in SLE patients and healthy controls.

  Haplotype                                                SLE (*n* (%))    Controls (*n* (%))   *χ* ^2^   *P*            OR (95% CI)
  -------------------------------------------------------- ---------------- -------------------- --------- -------------- ----------------------
  rs10030173, rs2119882, rs2165667, rs4861722, rs6847693                                                                  
  CCTAT                                                    44.05 (0.045)    27.21 (0.028)        4.135     **0.042031**   1.650 (1.014, 2.686)
  CTAGC                                                    341.42 (0.346)   331.12 (0.337)       0.241     0.623479       1.049 (0.866, 1.270)
  CTAGT                                                    38.30 (0.039)    19.92 (0.020)        5.983     **0.014466**   1.962 (1.133, 3.400)
  TCTAT                                                    135.01 (0.137)   180.70 (0.184)       8.071     **0.004512**   0.702 (0.549, 0.897)
  TCTGT                                                    117.73 (0.119)   118.09 (0.120)       0.001     0.974785       0.996 (0.757, 1.309)
  TTAGC                                                    217.53 (0.220)   216.35 (0.220)       0.003     0.954914       1.006 (0.811, 1.249)

SLE: systemic lupus erythematosus; SNPs: single-nucleotide polymorphisms; *MTNR1a*: *melatonin receptor 1a*; OR: odds ratio. Total *χ*^2^ = 16.556, *P* = 0.005. All the haplotypes with a frequency \< 0.03 were ignored in the analysis.

###### 

Haplotype analysis of three SNPs in *MTNR1b* gene in SLE patients and healthy controls.

  Haplotype                          SLE (*n* (%))    Control (*n* (%))   *χ* ^2^   *P*        OR (95% CI)
  ---------------------------------- ---------------- ------------------- --------- ---------- ----------------------
  rs1562444, rs10830962, rs3781637                                                             
  CAT                                296.17 (0.299)   260.80 (0.265)      2.573     0.108701   1.175 (0.965, 1.430)
  CGC                                130.72 (0.132)   127.39 (0.129)      0.014     0.906006   1.016 (0.782, 1.320)
  CGT                                144.94 (0.146)   137.77 (0.140)      0.123     0.725622   1.046 (0.813, 1.346)
  GAT                                408.55 (0.413)   442.60 (0.450)      3.208     0.073303   0.849 (0.710, 1.016)

SLE: systemic lupus erythematosus; SNPs: single-nucleotide polymorphisms; *MTNR1b*: *melatonin receptor 1b*; OR: odds ratio. Total *χ*^2^ = 3.762, *P* = 0.288. All the haplotypes with a frequency \< 0.03 were ignored in the analysis.

###### 

Haplotype analysis of three SNPs in AANAT gene in SLE patients and healthy controls.

  Haplotype                       SLE (*n* (%))    Control (*n* (%))   *χ* ^2^   *P*            OR (95% CI)
  ------------------------------- ---------------- ------------------- --------- -------------- ----------------------
  rs8150, rs3760138, rs12942767                                                                 
  CGG                             339.49 (0.344)   324.11 (0.329)      0.559     0.454842       1.074 (0.891, 1.295)
  CTG                             244.50 (0.247)   315.27 (0.320)      12.475    **0.000415**   0.701 (0.576, 0.854)
  GGA                             43.12 (0.044)    44.37 (0.045)       0.018     0.894335       0.971 (0.633, 1.492)
  GGG                             347.39 (0.352)   291.50 (0.296)      7.336     **0.006775**   1.299 (1.075, 1.571)

SLE: systemic lupus erythematosus; SNPs: single-nucleotide polymorphisms; *AANAT*: *arylalkylamine N-acetyltransferase*; OR: odds ratio. Total *χ*^2^ = 14.211, *P* = 0.003. All the haplotypes with a frequency \< 0.03 were ignored in the analysis.

[^1]: Guest Editor: Minggang Zhang
